Statement delivered at the 13th Intergovernmental Negotiating Body (INB 13)
On 17 February 2025, IFPMA delivered a statement at the INB 13.
The biopharmaceutical industry plays a crucial role in pandemic preparedness and response, driving the innovation needed to create pharmaceutical and other relevant products for future health crises.
In strengthening pandemic preparedness and response, there needs to be a clear focus on how to maintain the scientific research on pathogens of pandemic potential, while enhancing equitable access to vaccines and treatments in the event of a pandemic emergency. This can only happen through a robust intellectual property system, which must be safeguarded.
The pharmaceutical industry is committed to expanding access to its products during pandemic emergencies through various means, including donations, equity-based tiered pricing, voluntary licensing, and voluntary technology transfers on mutually agreed terms.
Each pathogen with pandemic potential is unique, and so too will be the response of each company. Different situations and countries may require various interventions at different stages of a pandemic emergency. Therefore, it is crucial to establish a system that is flexible enough to allow a wide variety of companies to leverage their skills and expertise.
To strengthen equitable access, we call on Member States to focus on measures both before and during a pandemic to support healthcare systems, enhance surveillance mechanisms, improve regulatory procedures, develop accurate forecasts, and ensure that companies receive the necessary orders to guide the scale up of production. By overcoming these barriers, Member States can help ensure that life-saving innovations reach those in need. This preparedness and response system must operate effectively at global, regional, and country levels.
We remain dedicated to sharing our experience and providing our expertise to support global health efforts and enhance pandemic preparedness and response.
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere.
ifpma.org
To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
